[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650249":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":11,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"SiBionics, Co, Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adult patients with T1DM","EXPERIMENTAL",null,[13],"Device: GS3 CGM",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","GS3 CGM","Wearing CGM for a consecutive 14 days",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Xiaodong Zhao","CONTACT","0533-3570000","xd.zhao26@outlook.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Zibo Central Hospital","RECRUITING","Zibo","Shandong","255100","China","CN",{"type":36,"coordinates":37},"Point",[38,39],118.06333,36.79056,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100650249","evaluation-of-the-accuracy-and-safety-of-a-continuous-glucose-monitoring-system-100650249",false,"NCT07745244","Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System","Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System Across Varying Blood Glucose Ranges","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagonsed with T1D\n* Venous blood sampling access can be established in the forearm\n* Capable of independently reading instructions and complying with the clinical trial requirements\n* Willing to sign the Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* Severe hypoglycemia within the past 6 month\n* Heart failure or hemiplegic sequelae due to prior cerebrovascular disease\n* Severe skin conditions at the sensor wear site\n* Extensive systemic skin disorders\n* Coagulation disorders confirmed by the investigator\n* Anemia or abnormal hematocrit\n* Blood donation within the past 6 months\n* Pregnancy (defined as positive urine test in women ≤55 years), lactation, or plans for pregnancy within ≤30 days\n* Current or recent (≤1 month) participation in other clinical trials\n* Planned MRI\u002FCT scans during sensor wear\n* Allergy to medical adhesives or alcohol\n* Conditions impairing comprehension of informed consent or study procedures\n* Other exclusionary conditions per investigator's discretion","ALL","18 Years",{"count":55,"type":56},36,"ESTIMATED","INTERVENTIONAL",[59],"NA","The study is to evaluate the accuracy and safety of a real-time CGM system among adult patients with type 1 diabetes with respect to reference venous plasma sample measurements.",[62,63,64],"type1diabetes","CGM","T1D","2026-07-29",{"date":67,"type":68},"2026-08-04","ACTUAL",{"date":70,"type":68},"2026-06-01",{"date":72,"type":56},"2027-12-01",{"name":5,"class":6},1]